Issue 24: Shortening Drug Development Timelines With Asian Ethnobridging Trials

Discover how local ethnobridging studies during Phase I clinical trials, in the target population, can reduce drug development timelines by the number of years typically needed to complete clinical development in a target region, as compared with North America or Europe.

In addition, the speaker will also cover how A Phase I ethnobridging strategy allows for patient recruitment in “global” safety and efficacy trials (Phases II and III) without repeating Phase I development in that region and population.